Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,070,852
  • Shares Outstanding, K 44,923
  • Annual Sales, $ 1,483 M
  • Annual Income, $ 514,800 K
  • 60-Month Beta 0.49
  • Price/Sales 6.02
  • Price/Cash Flow 16.59
  • Price/Book 2.60
Trade UTHR with:

Options Overview Details

View History
  • Implied Volatility 34.58%
  • Historical Volatility 18.90%
  • IV Percentile 26%
  • IV Rank 23.82%
  • IV High 51.09% on 02/18/21
  • IV Low 29.42% on 06/24/21
  • Put/Call Vol Ratio 0.01
  • Today's Volume 69
  • Volume Avg (30-Day) 206
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,548
  • Open Int (30-Day) 1,542

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 3.43
  • Number of Estimates 5
  • High Estimate 3.85
  • Low Estimate 3.12
  • Prior Year 3.84
  • Growth Rate Est. (year over year) -10.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
196.39 +2.08%
on 09/22/21
216.50 -7.40%
on 09/01/21
-6.45 (-3.12%)
since 08/23/21
3-Month
173.56 +15.50%
on 06/24/21
216.90 -7.57%
on 08/06/21
+25.83 (+14.79%)
since 06/23/21
52-Week
98.37 +103.79%
on 09/24/20
216.90 -7.57%
on 08/06/21
+99.92 (+99.37%)
since 09/23/20

Most Recent Stories

More News
United Therapeutics Releases its Annual Corporate Responsibility Report

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the release of its second annual Corporate Responsibility Report with 2020 highlights, providing stakeholders important...

UTHR : 200.47 (-0.72%)
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021

and , Sept. 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today presented new clinical data from the study evaluating Tyvaso DPI™ (treprostinil) in patients with pulmonary...

UTHR : 200.47 (-0.72%)
MNKD : 4.75 (+1.93%)
United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch "Braving NeuroBLASToma" in Honor of Childhood Cancer Awareness Month

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it is joining forces with former NFL player and his daughter Leah, a survivor of high-risk neuroblastoma, to launch...

UTHR : 200.47 (-0.72%)
United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present data from a clinical trial studying Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial...

UTHR : 200.47 (-0.72%)
MNKD : 4.75 (+1.93%)
U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics' Tyvaso(R) Patent

Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) against U.S. Patent No. 10,716,793 ('793 patent), owned by...

UTHR : 200.47 (-0.72%)
LQDA : 2.78 (-0.36%)
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up

United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.

MNKD : 4.75 (+1.93%)
LLY : 232.18 (+1.70%)
MDT : 130.64 (+1.34%)
UTHR : 200.47 (-0.72%)
Innovators in Pharma Sectors See Potential, Promise in Providing Improved Treatments

/PRNewswire/ --  in for men and women of most racial and ethnic groups, heart disease is a pervasive health challenge that destroys lives. The Center for Disease Control and Prevention (CDC) reports...

JAZZ : 134.50 (+3.82%)
JNJ : 164.86 (+0.57%)
UTHR : 200.47 (-0.72%)
ABT : 125.30 (+0.52%)
LEXX : 6.76 (+0.60%)
United Therapeutics (UTHR) Q2 Earnings and Revenues Surpass Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 27.62% and 17.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

UTHR : 200.47 (-0.72%)
United Therapeutics: Q2 Earnings Snapshot

SILVER SPRING, Md. (AP) _ United Therapeutics Corp. (UTHR) on Wednesday reported second-quarter net income of $172.6 million.

UTHR : 200.47 (-0.72%)
United Therapeutics Corporation Reports Second Quarter 2021 Financial Results

and , Aug. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in the second quarter of 2021...

UTHR : 200.47 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability....

See More

Key Turning Points

3rd Resistance Point 206.32
2nd Resistance Point 204.90
1st Resistance Point 202.69
Last Price 200.47
1st Support Level 199.05
2nd Support Level 197.63
3rd Support Level 195.42

See More

52-Week High 216.90
Last Price 200.47
Fibonacci 61.8% 171.62
Fibonacci 50% 157.63
Fibonacci 38.2% 143.65
52-Week Low 98.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar